Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello's partner Merck presents data on investigational house dust mite sublingual allergy immunotherapy tablet

Tuesday, 4 Mar 2014 05:30pm EST 

Alk Abello A/S:Says ALK's partner in North America, Merck & Co Inc, known as MSD outside the USA and Canada, presents new data from a Phase IIb trial with its investigational sublingual house dust mite allergy immunotherapy tablet.Says the data is presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego, USA.Says the trial results showed that both doses of active treatment significantly reduced the average total nasal symptom score compared to placebo in adults with house dust mite-induced allergic rhinitis. 

Company Quote

0.6 +1.02%
19 Dec 2014